← SynDRA
LAZERTINIB
SynDRA canonical compound SYN0039918 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | tyrosine kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- JAK3 INHIBITOR
- KDR INHIBITOR
- SYK INHIBITOR
- tyrosine kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Drug classes
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- LAZCLUZE
- Lazcluze
- YH25448
- C-18112003-G
- GNS-1480
- GNS1480
- JNJ-73841937-AAA
- YH-25448
- JNJ-73841937
- GNS 1480
- YH 25448
- UNII-4A2Y23XK11
- 4A2Y23XK11
- Lazertinib [USAN]
- Lazertinib [INN]
- Lazertinib (YH25448,GNS-1480)
- CHEMBL4558324
- SCHEMBL17670400
- GTPL10136
- BCP30440
- EX-A1912
- s8724
- WHO 10587
- CCG-270023
- YH-25448;GNS-1480
- BS-15742
- Compound 73 [WO2016060443A2]
- HY-109061
- AK00779508
- CS-0032992
- A16827
- CN(C)CC=1C(=NN(C=1)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC)C1=CC=CC=C1
- lazertinibum
- RefChem:798668
- Leclaza
- Lazertinib?
- LAZERTINIB [INN]
- Lazertinib (USAN/INN)
- Lazertinib [USAN:INN]
Look up LAZERTINIB in the interactive SynDRA portal →